BioLineRx (BLRX) vs CNS Pharmaceuticals (CNSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CNS Pharmaceuticals is the larger company by market cap ($5.3 million vs $4.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | CNSP |
|---|---|---|
| Share price | $0.9639 | $3.56 |
| Market cap | $4.80M | $5.25M |
| 1-day change | -8.20% | -12.75% |
| YTD return | -65.20% | — |
| 1-year return | -70.34% | — |
| 5-year return | -99.07% | — |
| EPS (TTM) | $0.00 | $-11.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.18M | — |
| Revenue growth (YoY) | -95.92% | — |
| Net income (latest FY) | $-2.03M | $-15.85M |
| Gross margin | 80.51% | — |
| Operating margin | -871.78% | — |
| Net margin | -171.69% | — |
| 52-week high | $3.95 | $10.54 |
| 52-week low | $0.78 | $1.90 |
| Distance from 52-week high | -75.60% | -66.22% |
| Analyst consensus | none | none |
| Avg. price target upside | +2182.39% | +180.90% |
| Average volume | 23.43K | 9.30K |
| Shares outstanding | 4.98M | 1.48M |
| Employees | 20 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About CNS Pharmaceuticals
CNSP stock →CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
BLRX vs CNSP FAQ
Which is bigger, BioLineRx or CNS Pharmaceuticals?
CNS Pharmaceuticals (CNSP) is larger, with a market capitalization of $5.25M compared with $4.80M for BioLineRx (BLRX).
Are BioLineRx and CNS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.